JCOG0911 INTEGRA study: a randomized screening phase II trial of interferonβ plus temozolomide in comparison with temozolomide alone for newly diagnosed glioblastoma

被引：0

作者：

Toshihiko Wakabayashi

Atsushi Natsume

Junki Mizusawa

Hiroshi Katayama

Haruhiko Fukuda

Minako Sumi

Ryo Nishikawa

Yoshitaka Narita

Yoshihiro Muragaki

Takashi Maruyama

Tamio Ito

Takaaki Beppu

Hideo Nakamura

Takamasa Kayama

Shinya Sato

Motoo Nagane

Kazuhiko Mishima

Yoko Nakasu

Kaoru Kurisu

Fumiyuki Yamasaki

Kazuhiko Sugiyama

Takanori Onishi

Yasuo Iwadate

Mizuhiko Terasaki

Hiroyuki Kobayashi

Akira Matsumura

Eiichi Ishikawa

Hikaru Sasaki

Akitake Mukasa

Takayuki Matsuo

Hirofumi Hirano

Toshihiro Kumabe

Nobusada Shinoura

Naoya Hashimoto

Tomokazu Aoki

Akio Asai

Tatsuya Abe

Atsuo Yoshino

Yoshiki Arakawa

Kenichiro Asano

Koji Yoshimoto

Soichiro Shibui

机构：

[1] Nagoya University Graduate School of Medicine,Department of Neurosurgery

[2] National Cancer Center Hospital,JCOG (Japan Clinical Oncology Group) Data Center/Operations Office

[3] Cancer Institute Hospital,Radiation Oncology Department

[4] Saitama Medical University International Medical Center,Department of Neuro

[5] National Cancer Center Hospital,Oncology/Neurosurgery

[6] Tokyo Women’s Medical University,Department of Neurosurgery and Neuro

[7] Nakamura Memorial Hospital,Oncology

[8] Iwate Medical University,Department of Neurosurgery

[9] Kumamoto University Graduate School of Medicine,Department of Neurosurgery

[10] Yamagata University Graduate School of Medicine,Department of Neurosurgery

[11] Kyorin University Faculty of Medicine,Department of Neurosurgery

[12] Shizuoka Cancer Center,Department of Neurosurgery

[13] Hiroshima University,Department of Neurosurgery

[14] Graduate School of Biomedical and Health Sciences,Department of Neurosurgery

[15] Hiroshima University Hospital,Department of Neurosurgery

[16] Ehime University Graduate School of Medicine,Department of Clinical Oncology & Neuro

[17] Chiba University Graduate School of Medicine,oncology Program

[18] Kurume University Graduate School of Medicine,Department of Neurosurgery

[19] Hokkaido University Graduate School of Medicine,Department of Neurosurgery

[20] University of Tsukuba,Department of Neurosurgery

[21] Keio University School of Medicine,Department of Neurosurgery

[22] The University of Tokyo Hospital,Department of Neurosurgery, Faculty of Medicine

[23] Nagasaki University Graduate School of Medicine,Department of Neurosurgery

[24] Kagoshima University Graduate School of Medical and Dental Sciences,Department of Neurosurgery

[25] Tohoku University Graduate School of Medicine,Department of Neurosurgery

[26] Kitasato University School of Medicine,Department of Neurosurgery

[27] Tokyo Metropolitan Cancer and Infectious Disease Center Komagome Hospital,Department of Neurosurgery

[28] Osaka University Graduate School of Medicine,Department of Neurosurgery

[29] Kitano Hospital,Department of Neurosurgery

[30] Kansai Medical University,Department of Neurosurgery

[31] Oita University Faculty of Medicine,Department of Neurosurgery

[32] Nihon University Graduate School of Medicine,Department of Neurosurgery

[33] Kyoto University Graduate School of Medicine,Department of Neurosurgery

[34] Hirosaki University Graduate School of Medicine,Department of Neurological Surgery

[35] Kyushu University,Department of Neurosurgery

来源：

Journal of Neuro-Oncology | 2018年 / 138卷

关键词：

Glioblastoma; Interferon-beta; Temozolomide; MGMT; RCT;

D O I：

暂无

中图分类号：

学科分类号：

摘要：

引用

页码：627 / 636

页数：9

共 50 条

[41] TIME TO FUNCTIONAL AND COGNITIVE DECLINE IN A PHASE 3 TRIAL OF TUMOR TREATING FIELDS WITH TEMOZOLOMIDE VERSUS TEMOZOLOMIDE ALONE IN PATIENTS WITH NEWLY DIAGNOSED GLIOBLASTOMA
Nicholas, Garth A.
Hirte, Holger
Easaw, Jacob
Muanza, Thierry
Roberge, David
Mathieu, David
Pitz, Marshall
NEURO-ONCOLOGY, 2017, 19 : 138 - 138
[42] PHASE III TRIAL OF TUMOR TREATING FIELDS (TTFIELDS) TOGETHER WITH TEMOZOLOMIDE (TMZ) COMPARED TO TEMOZOLOMIDE ALONE IN PATIENTS WITH NEWLY DIAGNOSED GLIOBLASTOMA (GBM)
Farber, Ori
Weinberg, Uri
Palti, Yoram
NEURO-ONCOLOGY, 2013, 15 : 76 - 77
[43] Phase 2 trial of bavituximab with chemoradiation and adjuvant temozolomide in newly diagnosed glioblastoma
Ly, Ina
Richardson, Leland
Liu, Mofei
Muzikansky, Alona
Lou, Kevin
Reardon, David A.
Arrillaga-Romany, Isabel
Forst, Deborah Anne
Jordan, Justin T.
Lee, Eudocia Quant
Dietrich, Jorg
Nayak, Lakshmi
Wen, Patrick Y.
Chukwueke, Ugonma Nnenna
Giobbie-Hurder, Anita
Choi, Bryan D.
Batchelor, Tracy
Kalpathy-Cramer, Jayashree
Curry, William T.
Gerstner, Elizabeth R.
JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
[44] PHASE I STUDY OF VANDETANIB WITH RADIOTHERAPY AND TEMOZOLOMIDE FOR NEWLY DIAGNOSED GLIOBLASTOMA
Drappatz, Jan
Norden, Andrew D.
Wong, Eric T.
Doherty, Lisa M.
LaFrankie, Debra C.
Ciampa, Abigail
Kesari, Santosh
Sceppa, Christine
Gerard, Mary
Phan, Phuong
Schiff, David
Batchelor, Tracy T.
Ligon, Keith L.
Young, Geoffrey
Muzikansky, Alona
Weiss, Stephanie E.
Wen, Patrick Y.
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2010, 78 (01): : 85 - 90
[45] Phase II Study of Bevacizumab Plus Temozolomide During and After Radiation Therapy for Patients With Newly Diagnosed Glioblastoma Multiforme
Kortmann, Rolf-Dieter
STRAHLENTHERAPIE UND ONKOLOGIE, 2011, 187 (10) : 670 - 671
[46] Temozolomide Plus Bevacizumab in Elderly Patients with Newly Diagnosed Glioblastoma and Poor Performance Status: An ANOCEF Phase II Trial (ATAG)
Reyes-Botero, German
Cartalat-Carel, Stephanie
Chinot, Olivier L.
Barrie, Maryline
Taillandier, Luc
Beauchesne, Patrick
Catry-Thomas, Isabelle
Barriere, Jerome
Guillamo, Jean-Sebastien
Fabbro, Michel
Frappaz, Didier
Benouaich-Amiel, Alexandra
Le Rhun, Emilie
Campello, Chantal
Tennevet, Isabelle
Ghiringhelli, Francois
Tanguy, Marie-Laure
Mokhtari, Karima
Honnorat, Jerome
Delattre, Jean-Yves
ONCOLOGIST, 2018, 23 (05): : 524 - +
[47] A PHASE I STUDY OF SORAFENIB WITH RADIATION AND TEMOZOLOMIDE IN NEWLY DIAGNOSED GLIOBLASTOMA
Colman, Howard
Gilbert, Mark
Yung, W. K. Alfred
Aldape, Ken
De Groot, John
Conrad, Charles
Levin, Victor
Groves, Morris
Loghin, Monica
Chris, Pelloski
Puduvalli, Vinay
NEURO-ONCOLOGY, 2011, 13 : 61 - 61
[48] Phase II Study of Bevacizumab Plus Temozolomide During and After Radiation Therapy for Patients With Newly Diagnosed Glioblastoma Multiforme
Lai, Albert
Tran, Anh
Nghiemphu, Phioanh L.
Pope, Whitney B.
Solis, Orestes E.
Selch, Michael
Filka, Emese
Yong, William H.
Mischel, Paul S.
Liau, Linda M.
Phuphanich, Surasak
Black, Keith
Peak, Scott
Green, Richard M.
Spier, Cynthia E.
Kolevska, Tatjana
Polikoff, Jonathan
Fehrenbacher, Louis
Elashoff, Robert
Cloughesy, Timothy
JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (02) : 142 - 148
[49] Temozolomide in Elderly Patients With Newly Diagnosed Glioblastoma and Poor Performance Status: An ANOCEF Phase II Trial
Perez-Larraya, Jaime Gallego
Ducray, Francois
Chinot, Olivier
Catry-Thomas, Isabelle
Taillandier, Luc
Guillamo, Jean-Sebastien
Campello, Chantal
Monjour, Annick
Cartalat-Carel, Stephanie
Barrie, Maryline
Huchet, Aymeri
Beauchesne, Patrick
Matta, Mona
Mokhtari, Karima
Tanguy, Marie-Laure
Honnorat, Jerome
Delattre, Jean-Yves
JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (22) : 3050 - 3055
[50] AVASTIN AND TEMOZOLOMIDE FOLLOWING RADIATION AND CHEMOTHERAPY FOR NEWLY DIAGNOSED GLIOBLASTOMA: RESULTS OF A PHASE II STUDY
Nicholas, M. K.
Chmura, S.
Paleologos, Nina
Krouwer, Hendrikus
Malkin, Mark
Junck, Larry
Vick, Nicholas A.
Lukas, Rimas V.
NEURO-ONCOLOGY, 2011, 13 : 88 - 89

← 1 2 3 4 5 →